MiNK Therapeutics (NASDAQ:INKT) Issues Quarterly Earnings Results

MiNK Therapeutics (NASDAQ:INKT) released its earnings results on Wednesday. The company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.16, Zacks reports.

Here are the key takeaways from MiNK Therapeutics’ conference call:

• MiNK has initiated a randomized Phase II ARDS trial enrolling 90 patients, comparing agenT-797 plus standard care with placebo plus standard care. The company says the protocol could transition seamlessly to Phase III, with preliminary data targeted for the second half of 2026; endpoints include survival and ventilator-free days.
• Management highlighted Phase II gastric cancer results in which median overall survival exceeded 23 months in an immune-primed cohort, with some patients still alive years after treatment. These are company-cited observations from a heavily pretreated population, and follow-up is ongoing.
• MiNK reported that the same agenT-797 product showed different immune activity in cancer and ARDS patient analyses, and said it is evaluating biomarkers that may help identify patients most likely to respond. The findings are early translational evidence, not proof of clinical benefit in the randomized trial.
• MiNK ended the first quarter with approximately $9.5 million in cash, after repaying about $5.2 million of debt and raising roughly $3 million through an at-the-market offering. Management expects at least 12 months of runway, including the ARDS trial, while the cash balance and ATM financing indicate continued funding needs may remain relevant.

MiNK Therapeutics Stock Up 3.9%

Shares of NASDAQ INKT traded up $0.39 during midday trading on Wednesday, reaching $10.40. 6,528 shares of the company were exchanged, compared to its average volume of 100,029. The stock’s 50-day moving average price is $11.19 and its 200-day moving average price is $11.24. The stock has a market cap of $53.04 million, a P/E ratio of -4.33 and a beta of 0.49. MiNK Therapeutics has a one year low of $8.48 and a one year high of $16.93.

Insider Activity at MiNK Therapeutics

In other news, CEO Jennifer Buell sold 6,938 shares of the stock in a transaction on Monday, October 12th. The stock was sold at an average price of $10.56, for a total value of $73,265.28. Following the completion of the transaction, the chief executive officer directly owned 74,195 shares in the company, valued at approximately $783,499.20. This represents a 8.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 20.40% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Zacks Research lowered MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. HC Wainwright began coverage on MiNK Therapeutics in a research note on Wednesday, November 4th. They issued a “buy” rating and a $38.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of MiNK Therapeutics in a research report on Friday, October 2nd. Finally, B. Riley Financial reissued a “buy” rating and set a $50.00 target price (up from $43.00) on shares of MiNK Therapeutics in a research note on Wednesday, October 21st. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $44.00.

About MiNK Therapeutics

MiNK Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company’s platform is based on invariant natural killer T (iNKT) cells, an immune-cell type that can recognize cancer-related targets and help stimulate broader anti-tumor immune responses. MiNK’s lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed to be developed as an off-the-shelf treatment. The candidate is being evaluated for use in oncology, including in combination with other cancer treatments such as immune checkpoint inhibitors.